# C_2019181EN.01000801.xml

| 27.5.2019 | EN | Official Journal of the European Union | C 181/8 |
| --- | --- | --- | --- |

27.5.2019

EN

Official Journal of the European Union

C 181/8

---

Prior notification of a concentration

(Case M.9274 — GlaxoSmithKline/Pfizer Consumer Healthcare Business)

(Text with EEA relevance)

(2019/C 181/04)

1.

This notification concerns the following undertakings:

| — | GlaxoSmithKline plc. (‘GSK’, United Kingdom), and |
| --- | --- |

—

GlaxoSmithKline plc. (‘GSK’, United Kingdom), and

| — | Pfizer Consumer Healthcare Business (‘Pfizer CH’, United States), controlled by Pfizer Inc. |
| --- | --- |

—

Pfizer Consumer Healthcare Business (‘Pfizer CH’, United States), controlled by Pfizer Inc.

GSK acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of Pfizer CH.

The concentration is accomplished by way of purchase of shares and assets.

2.

| — | GSK is a global pharmaceutical company active in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines, and consumer healthcare pharmaceuticals typically available without prescription, for various indications. GSK’s worldwide consumer health products span across various therapeutic areas, including pain management, respiratory health, nutrition and digestive health, skin health, and oral health. |
| --- | --- |

—

GSK is a global pharmaceutical company active in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines, and consumer healthcare pharmaceuticals typically available without prescription, for various indications. GSK’s worldwide consumer health products span across various therapeutic areas, including pain management, respiratory health, nutrition and digestive health, skin health, and oral health.

| — | Pfizer CH develops, manufactures and markets non-prescription medicines, vitamins, and nutritional products globally. Pfizer CH is active worldwide across various product categories, including pain management, respiratory health, gastrointestinal treatment, dietary supplements, and personal care products. |
| --- | --- |

—

Pfizer CH develops, manufactures and markets non-prescription medicines, vitamins, and nutritional products globally. Pfizer CH is active worldwide across various product categories, including pain management, respiratory health, gastrointestinal treatment, dietary supplements, and personal care products.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9274 — GlaxoSmithKline/Pfizer Consumer Healthcare Business

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| --- |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---